TABLE 1. Early and Late Tumor Response as Depicted by CT Perfusion.
| CT Perfusion Parameter | Pretreatment | At Week 2a | Percentage Change(p) |
Posttreatmentb | Percentage Change (p) |
|---|---|---|---|---|---|
|
| |||||
| Blood flow (mL/100 g/min) | 58.1 ± 50 | 46.4 ± 50.0 | −20.2 (0.1) | 27.7 ± 33.0 | −53.2 (0.0005) |
| Blood volume (mL/100 g) | 3.95 ± 3.1 | 2.7 ± 2.1 | −31.9 (0.01) | 1.4 ± 1.2 | −63.2 (0.001) |
| MTT (s) | 10.0± 4.1 | 9.5 ± 3.5 | −6.0 (0.47) | 9.4 ± 3.9 | −7.0 (0.5) |
| Permeability surface area product (mL/100 g/min) | 12.2 ± 11.4 | 9.4 ± 7.7 | −22.7 (0.1) | 4.3 ± 3.9 | −64.4 (0.005) |
| Tumor size (cm) | 8.1 ± 4.4 | 8.0 ± 4.6 | −3.0 (0.3) | 7.7 ± 4.4 | −4.0 (0.2) |
Note—Except where indicated otherwise, data are mean ± SD. A p value of < 0.05 indicates a significant difference between baseline and postantiangiogenic treatment values. MTT = mean transit time.
a
Refers to 2 weeks after initiation of bevacizumab therapy.
b
Refers to after completion of bevacizumab and radiation therapy.